

Patient Information Leaflet Juvéderm® VOLBELLA® with Lidocaine

1. NAME AND MODEL	1
2. INTENDED PURPOSE / INDICATIONS.....	1
3. CONTRAINDICATIONS, WARNING AND LIMITATIONS FOR USE.....	2
4. SPECIAL OPERATING INSTRUCTIONS FOR USE/PRECAUTIONS	2
5. INTENDED PERFORMANCE.....	4
6. UNDESIRABLE SIDE EFFECTS.....	4
7. SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION.....	5
8. RISKS & ASSOCIATED PRECAUTIONS.....	6
9. FOLLOW-UP CONSULTATION.....	6
10. DEVICE LIFETIME/DURATION OF TREATMENT EFFECT.....	6
11. COMPOSITION.....	7
12. RESIDUAL MATERIAL	7
13. ADDITIONAL INFORMATION / CONTACT	7

1. NAME AND MODEL

This product is Juvéderm® VOLBELLA® with Lidocaine.

Each box of Juvéderm® VOLBELLA® with Lidocaine contains 2 syringes, each filled with 1 mL hyaluronic acid injectable gel.

Product Description / What is Juvéderm® VOLBELLA® with Lidocaine?

Juvéderm® VOLBELLA® with Lidocaine is a smooth, clear, colourless gel which contains:

- hyaluronic acid to help retain natural moisture and softness in the skin,
- lidocaine (local anaesthetic) which helps improve comfort to the patient during injection.

2. INTENDED PURPOSE / INDICATIONS

What is the use of Juvéderm® VOLBELLA® with Lidocaine?

Juvéderm® VOLBELLA® with Lidocaine is an injectable implant intended to treat any fine lines, medium-sized or infraorbital (area under the eyes or tear trough area) skin depressions due to conditions such as premature ageing.

Juvéderm® VOLBELLA® with Lidocaine can also be used for enhancement and pouting of the lips.

Juvéderm® VOLBELLA® with Lidocaine is intended to be used via superficial or mid-dermis injection or lips mucosa injection by an authorised health care professional. For the treatment of the infraorbital skin depressions (also known as

tear trough area), it is recommended to inject in the submuscular / pre-periosteal plane. The presence of lidocaine is meant to reduce the patient's pain during treatment.

Who can be injected with Juvéderm® VOLBELLA® with Lidocaine?

Juvéderm® VOLBELLA® with Lidocaine is indicated for adults (over the age of 18).

3. CONTRAINDICATIONS, WARNING AND LIMITATIONS FOR USE

You should **not** use this product if:

- you are pregnant or breastfeeding,
- you suffer from untreated epilepsy,
- you tend to develop scarring,
- you are allergic to hyaluronic acid and/or to gram positive bacterial proteins, as hyaluronic acid is produced by *Streptococcus* type of bacteria,
- you are allergic to lidocaine or to similar local anaesthetics,
- you are suffering from a rare genetic (inherited) disease that causes build-up of porphyrins, which are the building blocks for haemoglobin,
- you are suffering from a skin inflammation or infection, such as acne or herpes in the treated areas.

Your medical practitioner should not inject Juvéderm® VOLBELLA® with Lidocaine into blood vessels (intravascular injection).

Your medical practitioner should not inject Juvéderm® VOLBELLA® with Lidocaine in the eyelids. Injection of Juvéderm® VOLBELLA® with Lidocaine in the bags under the eyes/tear trough area should only be done by health care professionals specifically trained in the appropriate injection technique and having a sound knowledge of the anatomy and physiology for this particular area.

4. SPECIAL OPERATING INSTRUCTIONS FOR USE/PRECAUTIONS

How should Juvéderm® VOLBELLA® with Lidocaine be used?

This product is designed to be injected in the appropriate areas requiring treatment by an authorised health care professional who has had appropriate training and experience in injection techniques for filling skin depressions, face contouring and volume restoration. Your medical practitioner should have informed you prior to treatment regarding the risks and side effects of the treatment as well as signs and symptoms of potential complications as early identification of complications is vital. Your medical practitioner may also consider pre- and post-intervention vision assessment following your assessment during initial consultation.

Before treatment:

Tell your medical practitioner:

1) If you are using the following medications:

- anti-coagulation medication (substances that can prolong bleeding), such as:
 - warfarin,
 - acetylsalicylic acid,
 - nonsteroidal anti-inflammatory drugs,
 - other substances known to increase clotting time such as herbal supplements with garlic or ginkgo biloba.
- medicines that reduce or inhibit hepatic metabolism (cimetidine, beta-blockers). Their use is not recommended due to the presence of lidocaine.

2) If you have had any prior treatments with facial injectables.

3) If you are suffering from any of the following medical conditions:

- History of, or currently suffering from, autoimmune disease or immune deficiency or immunosuppressive therapy. Your medical practitioner will therefore decide on the indication on a case-by-case basis, according to the nature of the disease and its corresponding treatment and shall also advise you if any specific monitoring will be required in your case. Your medical practitioner may also require you to have skin testing for hypersensitivity before any injection is administered and may also refrain from injecting the product if the disease is active.
- History of streptococcal disease (such as recurrent sore throats or acute rheumatic fever). Your medical practitioner may require you to have skin testing for hypersensitivity before any injection is administered. In the event of acute rheumatic fever with heart complications, it is recommended that you do not receive treatment with Juvéderm® VOLBELLA® with Lidocaine.
- Symptoms of heart disease.
- History of severe and/or multiple allergies. According to the nature of the allergy, your medical practitioner will decide on the use of the product as well as whether you require any specific monitoring. In particular, a decision may be taken to propose skin testing for hypersensitivity or suitable preventive treatment for you prior to any injection. If you have a history of anaphylactic shock, it is recommended that you do not receive treatment with Juvéderm® VOLBELLA® with Lidocaine.
- Pre-existing tendency for swelling under the eyes. Your medical practitioner will consider your history as well as the anatomy and physiology of the area under your eyes in evaluating whether treatment with Juvéderm® VOLBELLA® with Lidocaine is suitable for you in this region. If you are to be treated, your medical practitioner will advise you if there is a potential for increased risk of prolonged swelling in this area.

You should not have this procedure at the same time as laser treatment, deep chemical peels or dermabrasion. For surface peels, it is not recommended to receive treatment with Juvéderm® VOLBELLA® with Lidocaine if there is significant inflammation from the skin peel treatment still present.

This product is not intended to be injected into an area which has been previously treated with a permanent implant to limit risk of chronic/serious adverse events such as granuloma/areas of inflammation which have been reported with subsequent injections.

After treatment:

You should not use any makeup for at least 12 hours following the injection treatment.

You should avoid extended exposure to the sun, ultraviolet (UV) rays and temperatures below 0°C, as well as any sauna or hammam sessions, during the two weeks following the injection treatment.

5. INTENDED PERFORMANCE

Juvéderm® VOLBELLA® with Lidocaine is an injectable implant intended to treat any fine lines, medium-sized or infraorbital skin depressions due to conditions such as premature ageing. Juvéderm® VOLBELLA® with Lidocaine can also be used for enhancement and pouting of the lips. Juvéderm® VOLBELLA® with Lidocaine is intended to be used via superficial or mid-dermis injection or lips mucosa injection by an authorised health care professional. For the treatment of the infraorbital skin depressions (also known as tear trough area), it is recommended to inject in the submuscular / pre-periosteal plane. The presence of lidocaine is meant to reduce the patient's pain during treatment.

6. UNDESIRABLE SIDE EFFECTS

What are the possible side effects?

The most common side effects include temporary reactions at the treatment site, which are consistent with other facial-injection procedures.

Potential side effects associated with implantation of this product may occur immediately or may be delayed. These include but are not limited to:

- Inflammatory reactions (such as redness, swelling, acne, herpes, etc), which may be associated with itching and/or pain on pressure and/or abnormal skin sensation, occurring after the injection. These reactions may last for a week.
- Bruising (haematomas).
- Allergic reaction (such as urticaria, dermatitis, hypersensitivity, etc).
- Hardened mass at the injection site.
- Staining or discolouration of the injection site might be observed, especially when hyaluronic acid dermal filler is injected too superficially and/or in thin skin (Tyndall effect).
- Poor effect or weak filling effect.
- Rare but serious adverse events associated with intravascular injection of dermal fillers in the face and tissue compression have been reported. These complications, which have been reported for facial injections, can include temporary or permanent vision impairment, blindness, slowing down of blood supply to the brain (cerebral ischaemia) or bleeding in that area leading to stroke (cerebral haemorrhage), skin tissue cell-death (necrosis) and damage to underlying tissues/structures.

- Pus formation, inflammation and immediate or delayed allergic reactions after hyaluronic acid and/or lidocaine injections have also been reported.
- Other side effects can occur such as unsatisfactory results after treatment, device migration, inflammatory nodule, cyst, tissue damage, necrosis, infection, autoimmune disorder, vision disorder/loss, vascular occlusion, stroke, neurological symptoms (such as headache, dizziness, paresthesia), cardiac complications (such as arrhythmia).

Please see section 7: *SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION* for further information.

When should I call my medical practitioner?

If you believe that you have experienced an undesirable effect related to Juvéderm® VOLBELLA® with Lidocaine injectable gel, you should call your medical practitioner and/or the local sponsor of the product, AbbVie Pty Ltd, please see section 13: *ADDITIONAL INFORMATION / CONTACT*.

7. SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION

What are the symptoms or signs that could indicate the device is malfunctioning or treatment is not as expected?

Your medical practitioner will stop the procedure if any of the following symptoms are seen during the injection: changes in vision, signs of stroke, whitening/paling of the skin or unusual pain during or shortly after the procedure. If immediate whitening/paling occurs, the injection should be stopped and the area massaged until it returns to a normal colour. If normal skin colouring does not return, your medical practitioner may not continue with the treatment.

There are potential side effects associated with implantation of this product, which may occur immediately or may be delayed. Please see section 6: *UNDESIRABLE SIDE EFFECTS* for further information.

What precautions and other measures should you take if the performance of the device changes or if you experience any undesirable side effects?

Before treatment:

Your medical practitioner should have discussed with you the product's indications, contra-indications, incompatibilities and potential undesirable effects/risks associated with dermal filler injection and ensure that you are aware of the signs and symptoms of potential complications.

After treatment:

Please report the following to your medical practitioner as soon as possible for appropriate treatment:

- inflammatory reactions for more than one week or
- any other side effect that has developed.

If you believe that you have experienced an undesirable effect related to Juvéderm® VOLBELLA® with Lidocaine injectable gel, you should call your medical practitioner and/or the local sponsor of the product, AbbVie Pty Ltd, please see section 13: *ADDITIONAL INFORMATION / CONTACT*.

8. RISKS & ASSOCIATED PRECAUTIONS

What are residual risks?

Residual risks could arise due to any shortcoming of the protection measures adopted as part of the medical device guideline. Please refer to information provided in section 12: *RESIDUAL MATERIAL*.

What are risks that could arise from interaction of Juvéderm® VOLBELLA® with Lidocaine with other equipment or material?

Juvéderm® VOLBELLA® with Lidocaine does not interact with other medical and/or electrical equipment and is compatible with fields used for magnetic resonance imaging.

Hyaluronic acid is known to be incompatible with quaternary ammonium salts such as benzalkonium chloride.

Juvéderm® VOLBELLA® with Lidocaine contains lidocaine, there is no known interaction with other local anaesthetics.

Because of the risks associated with treatment with Juvéderm® VOLBELLA® with Lidocaine, the following precautions and other measures, should be taken:

By Health care professionals/Medical practitioners:

Juvéderm® VOLBELLA® with Lidocaine should never be placed in contact with quaternary ammonium salts such as benzalkonium chloride or with medical-surgical instrumentation which has been treated with this type of substance.

By the patient:

Please refer to Section 4: *SPECIAL OPERATING INSTRUCTIONS FOR USE/PRECAUTIONS* for further information with regards to precautions to be followed before and after treatment with Juvéderm® VOLBELLA® with Lidocaine.

9. FOLLOW-UP CONSULTATION

What is the nature and frequency of regular follow-up, examination, monitoring or maintenance following treatment that you need to undertake?

It is suggested to have a follow-up consultation with your healthcare professional approximately 2 weeks after the procedure. This is an opportunity to discuss any potential adverse effects you have observed.

A touch-up treatment (for achieving optimal correction) with Juvéderm® VOLBELLA® with Lidocaine might be required which can also be completed at this follow-up appointment.

10. DEVICE LIFETIME/DURATION OF TREATMENT EFFECT

What is the lifetime of the product? What could shorten or lengthen the treatment lifetime?

The correction is temporary. The degree and duration of the correction depend on the character of the defect treated, the tissue stress at the implant site, the depth of the implant in the tissue and the injection technique. It will also vary with the individual patient being treated.

What precautions and other measures should you take at, or near, the end of the expected treatment lifetime?

For maintaining optimal correction, a repeat treatment with Juvéderm® VOLBELLA® with Lidocaine might be required. You can contact your medical practitioner for further information.

Under what circumstances should you contact a health professional in relation to the operation/use of Juvéderm® VOLBELLA® with Lidocaine?

Please refer to information provided in section 7: *SYMPTOMS OR SIGNS OF DEVICE OR TREATMENT MALFUNCTION*.

11. COMPOSITION

What material & substances are included in Juvéderm® VOLBELLA® with Lidocaine?

Each 1 mL syringe of Juvéderm® VOLBELLA® with Lidocaine contains:

- Hyaluronic acid gel: 15 mg,
- Lidocaine (lignocaine) hydrochloride monohydrate: 3 mg,
- Phosphate buffer pH 7.2 to make 1 mL.

12. RESIDUAL MATERIAL

What are the manufacturing residuals that could pose a risk to you?

This product does not contain any manufacturing residuals that can pose a risk to patients.

13. ADDITIONAL INFORMATION / CONTACT

What to do in case of any serious incident that occurs in relation to Juvéderm® VOLBELLA® with Lidocaine?

Any serious incident with Juvéderm® VOLBELLA® with Lidocaine should be reported to the manufacturer and to the Therapeutic Goods Administration.

If you believe you have experienced an incident/ side effect after treatment with Juvéderm® VOLBELLA® with Lidocaine injectable gel, you should contact Allergan Aesthetics by email to MedDeviceComplaintsAPAC@AbbVie.com or call 1800 252 224 and contact the Therapeutic Goods Administration at <https://www.tga.gov.au/>.

ALLERGAN

Allergan
Aesthetics

JUVÉDERM, VOLBELLA, and their designs are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates.
20075276 JUVÉDERM® VOLBELLA® with Lidocaine PIL, V 3.0
Date of preparation: 09 12 2022
© 2023 AbbVie. All rights reserved.